OBJECTIVE:To observe clinical efficacy and safety of Bifidobacterium triple viable capsules in the adjunctive treatment of Helicobacter pylori(Hp)positive chronic atrophic gastritis(CAG)complicated with anxiety-depression. METHODS:A total of 100 Hp positive CAG patients with anxiety-depression were divided into control group and observation group according to random number table,with 50 cases in each group. Control group was given standard triple therapy (rabeprazole+amoxicillin and clavulanate+levofloxacin). Observation group was additionally given Bifidobacterium triple viable capsules 0.42 g,tid. The treatment lasted for 14 d in both groups. Clinical efficacies,Hp eradication rates as well as HAMA and HAMD scores before and after treatment were all observed in 2 group. The occurrence of ADR was compared. RESULTS:Total response rate of observation group was 94.0%,and Hp eradication rate was 92.0%,which were significantly higher than 76.0% and 78.0% of control group, with statistical significance (P0.05). After treatment,HAMA and HAMD scores of 2 groups were decreased significantly,the observation group was significantly lower than the control group,with statistical significance (P0.05);治疗后,两组患者HAMA、HAMD评分显著降低,且观察组评分显著低于对照组,差异均有统计学意义(P<0.05).观察组患者不良反应发生率为4.0%,显著低于对照组的20.0%,差异有统计学意义(P<0.05).结论:双歧杆菌三联活菌胶囊辅助治疗伴有焦虑抑郁的Hp阳性CAG疗效显著,可显著提高Hp根除率,明显改善患者焦虑抑郁状态,降低不良反应发生率.
展开▼
